Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nektar Therapeutics - Common Stock
(NQ:
NKTR
)
65.25
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
922
Open
65.25
Bid (Size)
65.75 (500)
Ask (Size)
67.00 (500)
Prev. Close
65.25
Today's Range
65.25 - 65.25
52wk Range
6.480 - 77.97
Shares Outstanding
183,801,441
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NEKTAR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
March 27, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
March 26, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Performance
YTD
+50.3%
+50.3%
1 Month
-4.5%
-4.5%
3 Month
+52.7%
+52.7%
6 Month
+10.7%
+10.7%
1 Year
+539.7%
+539.7%
More News
Read More
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
March 25, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 25, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky
March 24, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 24, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
March 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
March 23, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
March 20, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
2 Healthcare Stocks to Buy Before They Get Bought Out
↗
March 20, 2026
Via
The Motley Fool
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
March 19, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
March 19, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 18, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Deadline Approaching: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
March 18, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
March 17, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
March 17, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 17, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
March 17, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
March 16, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
March 16, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 14, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Law Offices of Howard G. Smith Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
March 13, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 13, 2026
From
Schall Law
Via
GlobeNewswire
Frequently Asked Questions
Is Nektar Therapeutics - Common Stock publicly traded?
Yes, Nektar Therapeutics - Common Stock is publicly traded.
What exchange does Nektar Therapeutics - Common Stock trade on?
Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nektar Therapeutics - Common Stock?
The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market
What is the current price of Nektar Therapeutics - Common Stock?
The current price of Nektar Therapeutics - Common Stock is 65.25
When was Nektar Therapeutics - Common Stock last traded?
The last trade of Nektar Therapeutics - Common Stock was at 03/30/26 04:00 PM ET
What is the market capitalization of Nektar Therapeutics - Common Stock?
The market capitalization of Nektar Therapeutics - Common Stock is 11.99B
How many shares of Nektar Therapeutics - Common Stock are outstanding?
Nektar Therapeutics - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
